Skip to content
Research Article Open access CC BY 4.0

Benefits of Docetaxel for Metastatic Castration-Resistant Prostate Cancer Sudanese Patients and the Effective Number of Cycle and Dose (2013–2017)

Mawahib Ahmed Elawad Abu Elgasim, Yousra Abdelmoniem Suleiman, Ehssan M. Elnazir Ahmed ELmubark, Alaa Albukhari Alrayah Abdalmahmoud, Sujood Abdelmoneim Mohmmed Babkeir, Rogaia Omer, Rayayan Yasin, Khalida Esmaiel Adam Abaker, Roa Osman Ahmed Babker, Anfal Abdalrhman Alryah, Thowibaah Abdalrhman Alzain

International Research Journal of Oncology · pp. 53–61 · Published 2 Jul 2019

Abstract

Background: Prostate cancer remains the most common cancer in men worldwide and in Sudanese people. The initial treatment of choice for prostate cancer is androgen deprivation. If resistant to treatment, this leads to a state termed metastatic castration-resistant prostate cancer (mCRPC) which leads to the use of Docetaxel(Taxotere) which has been a mainstay of therapy for patients with mCRPC. This study aimed to determine the optimal number of cycles of DOcetaxel plus prednisone in patients with metastatic castration-resistant prostate cancer, through the evaluation of a number of parameters, such as performance status, prostate-specific antigen response and pain Methods: Retrospective study of (60) metastatic castration-resistant prostate cancer (mCRPC) Sudanese patients who received Docetaxel plus prednisone (duration, 2013–2017). Area; The Radiation and Isotopes Centre of Khartoum (RICK).Data collected by reviewing medical of records of patients confirmed (mCRPC). Outcomes: Including: performance status, prostate-specific antigen (PSA) response and pain. According to this study we found that docetaxel has an effective role in the treatment of mCRPC patients with an optimal number of6–8 cycles every 3 weeks and with a dose of 75 mg Conclusion: The benefits for using Docetaxel for mCRPC Sudanese patients: declined of PSA serum level, improvement of performance status and pain reduction. Effective optimal number of cycles 6 to 8 every 3 weeks and dose of 75 mg

Benefits Docetaxel mCRPC Sudanese men

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.